Tag: refractory acute myeloid leukemia

Home / refractory acute myeloid leukemia

Categories

Olutasidenib is approved by FDA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a suscepti...
refractory-acute-myeloid-leukemia

Scan the code